申请人:BRISTOL-MYERS SQUIBB COMPANY
公开号:US20210323966A1
公开(公告)日:2021-10-21
Compounds of formula (I) or a stereoisomer or pharmaceutically-acceptable salt thereof, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.